Oxcarbazepine-induced drug rash with eosinophilia and systemic symptoms syndrome presenting as exfoliative dermatitis
- 1*,
- 2,
- 1
- 1Department of Dermatology, Silchar Medical College, Silchar, Assam, India.
- 2Department of Dermatology, Burdwan Medical College, Burdwan, West Bengal, India.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Mahimanjan Saha
Department of Dermatology, Silchar Medical College, Silchar, Assam, India.
Email: mahimanjan@gmail.com
Copyright: © 2016 The Author(s). This is an open access article.
Published: Jan 1, 2016, Received: Mar 19, 2016, Accepted: Jun 8, 2016
Abstract
Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a type of severe adverse cutaneous drug reaction characterized by fever, skin eruption, hematological abnormalities, and internal organ involvement. Although anticonvulsant drugs are mainly implicated in DRESS, newer anticonvulsants such as oxcarbazepine-induced definite cases of DRESS syndrome are rare and oxcarbazepine-induced DRESS syndrome presenting as exfoliative dermatitis is even rarer. We report a case of a 35-year-old male who developed DRESS syndrome presenting as exfoliative dermatitis after taking oxcarbazepine for 3 weeks.
Keywords
Subject
Recommended articles
- Identification of risk factors for carbamazepine‑induced serious mucocutaneous adverse reactions: A case‑control study using data from spontaneous adverse drug reaction reports
Ilma Bertulyte, Sofie Schwan, Pär Hallberg · Journal of Pharmacology and Pharmacotherapeutics
Readers Also Viewed
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026
Knowledge, Attitude, and Practice on Digital Eye Strain Among Healthcare Students at a Private University in Northern Peninsular Malaysia
Lim Chin Hung, Subramani Parasuraman, Sam Aaseer Thamby
Jan 1, 2026